Physician profile
Daniel C Hamou
NPI 1548208473
$8,298.32
in general payments reported to CMS, 2019-2025
18 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $931 · 2021: $821 · 2022: $851 · 2023: $861 · 2024: $1,929 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,466 · Gift: $43.43 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,466.01 |
| Gift | $43.43 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,617.03 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Bausch & Lomb Americas INC. | $1,061.91 | 2024-2025 | Envista Mx60 Iol, Envista Aspire Iol, Envista Envy Iol |
| Abbvie INC. | $865.64 | 2022-2025 | |
| Glaukos Corporation | $826.72 | 2019-2025 | Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $422.15 | 2023-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $341.76 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.48 | 2019-2021 | |
| Allergan, INC. | $136.30 | 2021 | |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Genentech USA, INC. | $125.00 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $123.83 | 2025 | Xdemvy |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Sun Pharmaceutical Industries INC. | $122.11 | 2023 | Cequa |
| Kala Pharmaceuticals, INC. | $61.80 | 2019-2021 | |
| Dompe US, INC. | $43.67 | 2022-2024 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $33.63 | 2019-2024 | Dextenza |
| Oyster Point Pharma, INC. | $19.23 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hamou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.